FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378093237> ?p ?o ?g. }

• W4378093237 endingPage "1987" @default.
• W4378093237 startingPage "1979" @default.
• W4378093237 abstract "OBJECTIVE—To assess the efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes and inadequate glycemic control on diet and exercise. RESEARCH DESIGN AND METHODS—In a 24-week, randomized, double-blind, placebo-controlled, parallel-group study, 1,091 patients with type 2 diabetes and A1C 7.5–11% were randomized to one of six daily treatments: sitagliptin 100 mg/metformin 1,000 mg (S100/M1000 group), sitagliptin 100 mg/metformin 2,000 mg (S100/M2000 group), metformin 1,000 mg (M1000 group), metformin 2,000 mg (M2000 group) (all as divided doses administered twice daily [b.i.d.]), sitagliptin 100 mg q.d. (S100 group), or placebo. Patients who had an A1C &gt;11% or a fasting glucose value &gt;280 mg/dl after the run-in period were not eligible to be randomized; these patients could participate in an open-label substudy and were treated with S100/M2000 for 24 weeks. RESULTS—The mean baseline A1C was 8.8% in the randomized patients. The placebo-subtracted A1C change from baseline was −2.07% (S100/M2000), −1.57% (S100/M1000), −1.30% (M2000), −0.99% (M1000), and −0.83% (S100) (P &lt; 0.001 for comparisons versus placebo and for coadministration versus respective monotherapies). The proportion of patients achieving an A1C &lt;7% and &lt;6.5% was 66 and 44%, respectively, in the S100/M2000 group (P &lt; 0.001 vs. S100 or M2000). For the open-label cohort (n = 117; baseline A1C 11.2%) treated with S100/M2000, the within-group mean A1C change from baseline was −2.9%. The incidence of hypoglycemia was low (0.5–2.2%) across active treatment groups and not significantly different from that in the placebo group (0.6%). The incidence of gastrointestinal adverse experiences was similar for coadministration therapies compared with their respective metformin monotherapy. CONCLUSIONS—The initial combination of sitagliptin and metformin provided substantial and additive glycemic improvement and was generally well tolerated in patients with type 2 diabetes." @default.
• W4378093237 created "2023-05-25" @default.
• W4378093237 creator A5001485785 @default.
• W4378093237 creator A5022896675 @default.
• W4378093237 creator A5058310578 @default.
• W4378093237 creator A5061867713 @default.
• W4378093237 creator A5068650358 @default.
• W4378093237 date "2007-08-01" @default.
• W4378093237 modified "2023-10-16" @default.
• W4378093237 title "Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes" @default.
• W4378093237 cites W1975588287 @default.
• W4378093237 cites W1975877581 @default.
• W4378093237 cites W1979637205 @default.
• W4378093237 cites W1984588810 @default.
• W4378093237 cites W1989742048 @default.
• W4378093237 cites W1991940590 @default.
• W4378093237 cites W1993930772 @default.
• W4378093237 cites W1995404454 @default.
• W4378093237 cites W2018192866 @default.
• W4378093237 cites W2028038659 @default.
• W4378093237 cites W2042129134 @default.
• W4378093237 cites W2046645679 @default.
• W4378093237 cites W2048565142 @default.
• W4378093237 cites W2051462052 @default.
• W4378093237 cites W2054185381 @default.
• W4378093237 cites W2069150029 @default.
• W4378093237 cites W2079229392 @default.
• W4378093237 cites W2083473802 @default.
• W4378093237 cites W2085862152 @default.
• W4378093237 cites W2113936882 @default.
• W4378093237 cites W2126327417 @default.
• W4378093237 cites W2126693629 @default.
• W4378093237 cites W2145335273 @default.
• W4378093237 cites W2157841460 @default.
• W4378093237 cites W2159205789 @default.
• W4378093237 cites W2160234571 @default.
• W4378093237 cites W2171403951 @default.
• W4378093237 cites W2171512247 @default.
• W4378093237 cites W2337454357 @default.
• W4378093237 cites W3187729126 @default.
• W4378093237 cites W4235717978 @default.
• W4378093237 doi "https://doi.org/10.2337/dc07-0627" @default.
• W4378093237 hasPublicationYear "2007" @default.
• W4378093237 type Work @default.
• W4378093237 citedByCount "252" @default.
• W4378093237 countsByYear W43780932372012 @default.
• W4378093237 countsByYear W43780932372013 @default.
• W4378093237 countsByYear W43780932372014 @default.
• W4378093237 countsByYear W43780932372015 @default.
• W4378093237 countsByYear W43780932372016 @default.
• W4378093237 countsByYear W43780932372017 @default.
• W4378093237 countsByYear W43780932372018 @default.
• W4378093237 countsByYear W43780932372019 @default.
• W4378093237 countsByYear W43780932372020 @default.
• W4378093237 countsByYear W43780932372021 @default.
• W4378093237 countsByYear W43780932372022 @default.
• W4378093237 countsByYear W43780932372023 @default.
• W4378093237 crossrefType "journal-article" @default.
• W4378093237 hasAuthorship W4378093237A5001485785 @default.
• W4378093237 hasAuthorship W4378093237A5022896675 @default.
• W4378093237 hasAuthorship W4378093237A5058310578 @default.
• W4378093237 hasAuthorship W4378093237A5061867713 @default.
• W4378093237 hasAuthorship W4378093237A5068650358 @default.
• W4378093237 hasBestOaLocation W43780932371 @default.
• W4378093237 hasConcept C126322002 @default.
• W4378093237 hasConcept C134018914 @default.
• W4378093237 hasConcept C142724271 @default.
• W4378093237 hasConcept C168563851 @default.
• W4378093237 hasConcept C204787440 @default.
• W4378093237 hasConcept C27081682 @default.
• W4378093237 hasConcept C2777180221 @default.
• W4378093237 hasConcept C2778763485 @default.
• W4378093237 hasConcept C2779284873 @default.
• W4378093237 hasConcept C2780282729 @default.
• W4378093237 hasConcept C2780323712 @default.
• W4378093237 hasConcept C2780473172 @default.
• W4378093237 hasConcept C2910260750 @default.
• W4378093237 hasConcept C555293320 @default.
• W4378093237 hasConcept C71924100 @default.
• W4378093237 hasConcept C90924648 @default.
• W4378093237 hasConceptScore W4378093237C126322002 @default.
• W4378093237 hasConceptScore W4378093237C134018914 @default.
• W4378093237 hasConceptScore W4378093237C142724271 @default.
• W4378093237 hasConceptScore W4378093237C168563851 @default.
• W4378093237 hasConceptScore W4378093237C204787440 @default.
• W4378093237 hasConceptScore W4378093237C27081682 @default.
• W4378093237 hasConceptScore W4378093237C2777180221 @default.
• W4378093237 hasConceptScore W4378093237C2778763485 @default.
• W4378093237 hasConceptScore W4378093237C2779284873 @default.
• W4378093237 hasConceptScore W4378093237C2780282729 @default.
• W4378093237 hasConceptScore W4378093237C2780323712 @default.
• W4378093237 hasConceptScore W4378093237C2780473172 @default.
• W4378093237 hasConceptScore W4378093237C2910260750 @default.
• W4378093237 hasConceptScore W4378093237C555293320 @default.
• W4378093237 hasConceptScore W4378093237C71924100 @default.
• W4378093237 hasConceptScore W4378093237C90924648 @default.
• W4378093237 hasIssue "8" @default.
• W4378093237 hasLocation W43780932371 @default.

• next